News and Trends 8 Sep 2022 Integral Molecular joins FDA’s ISTAND program Integral Molecular has been accepted into the U.S. Food & Drug Administration (FDA)’s ISTAND (Innovative Science and Technology Approaches for New Drugs) pilot program. The program supports, and was created to expand, the drug development tool types listed in the 21st Century Cures legislation. A major goal of the pilot program is to qualify these […] September 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Aug 2022 World’s first CAR-T for treatment of inflammatory disorders of the central nervous system approved in China China’s National Medical Products (NMPA) has approved an investigational new drug application from IASO Bio for the new extended indication of neuromyelitis optica spectrum disorder (NMOSD). Neuromyelitis optica spectrum disorders previously known as Devic disease or neuromyelitis optica are inflammatory disorders of the central nervous system characterized by severe, immune-mediated demyelination and axonal damage predominantly targeting […] August 19, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Aug 2022 Carina Biotech raises funds for colorectal cancer research Australia’s Carina Biotech has raised A$7.5 million (US$5.2 million) at first close of its current funding round. Venture capital business Tenmile was the cornerstone investor, with support from existing investors. The capital raise enables Carina Biotech to complete its Investigational New Drug (IND) enabling studies and initiate a CAR-T clinical trial of its LGR5 CAR-T […] August 18, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Aug 2022 Regen BioPharma develops new approach for boosting CAR-T cell efficiency to treat solid tumors Regen BioPharma, Inc. has filed with the United States Patent and Trademark Office a provisional U.S. patent application covering the company’s novel approach for enabling chimeric antigen receptor (CAR)-T cell-based therapies to kill solid tumors through prevention of a process called “T cell exhaustion.” CAR-T cells are effective at treating certain lymphomas and leukemias with […] August 11, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 Poseida Therapeutics and Roche to focus on therapies for hematologic malignancies Poseida Therapeutics, Inc. has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. The global collaboration covers the research and development of multiple existing and novel off-the-shelf cell therapies against targets in multiple myeloma, B-cell lymphomas and other hematologic indications. “We are excited […] August 3, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Trinity, St. James’s and Legend Biotech collaborating on solid tumors Trinity College and St. James’s Hospital Dublin (SJH) in Ireland have entered into a strategic collaboration with Legend Biotech, a global biotechnology company developing, manufacturing and commercializing novel therapies. Together, they will develop 3D models exploring chimeric antigen receptor T-cell (CAR-T) cell therapies in solid tumors. CAR T-cell therapies are customized for each individual patient. […] June 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 Galapagos to acquire CellPoint and AboundBio to advance cell therapies Belgian headquartered biotech Galapagos NV has acquired CellPoint and AboundBio, a move the Belgian company said propels it into next-generation cell therapy. Galapagos said the acquisitions give it access to an innovative, scalable, decentralized and automated point-of-care cell therapy supply model as well as a next-generation fully human antibody-based therapeutics platform. Galapagos said the goal […] June 22, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2022 Immuneel Therapeutics raises $15M and starts patient trials for CAR-T cancer therapies Indian biotech start-up Immuneel Therapeutics has announced it has started patient dosing in a CAR-T trial named “IMAGINE.” The Indian company focuses on creating access to Chimeric Antigen Receptor T cell therapy (CAR-T) and other cellular immunotherapies for the management and treatment of cancers. The phase II trial is the first industry sponsored CAR-T trial […] June 21, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2022 TILT Biotherapeutics raises $10M to push ahead on cancer immunotherapies TILT Biotherapeutics (TILT), a clinical-stage Finnish biotech company developing cancer immunotherapies, has completed the first close of its financing round, raising $10.7 million. It was led by Lifeline Ventures and joined by Tesi (Finnish Industry Investment Ltd). The funding will be used to advance phase I/II programs in Europe and the U.S., using TILT-123 plus […] June 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Oct 2021 Gene-Edited T Cell Therapy Players Battle Safety Doubts Confidence in gene-edited T cell therapies from donor cells has faltered as Allogene Therapeutics paused all clinical development following the detection of an unexpected genetic change in a clinical trial. Industry experts see these events as a reality check for the nascent field. Off-the-shelf treatments that use genetically engineered T cells to treat diseases suffered […] October 22, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
In Depth 11 Oct 2021 A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology CAR-T therapy has been hailed as a cure for cancer, but what really is this ‘miraculous technology’ and what can we actually expect from it? The field of immuno-oncology is booming with billions of euros in investment. The ability to rewire our own immune system to fight cancer has certainly created huge expectations. After the […] October 11, 2021 - 10 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2021 Microbiome Medicines Could Power Up CAR-T Cell Therapies The microbiome could pave new cancer immunotherapy inroads for European biotechs, bolstered by preclinical findings that gut bacteria metabolites may help CAR-T cell therapies penetrate and kill solid tumors. A recent study conducted by researchers at Philipps-University Marburg, University Hospital Würzburg, and the Leeds-based company 4D Pharma showed that metabolites produced by the gut bacteria […] July 28, 2021 - 5 minutesmins - By Mark Zipkin Share WhatsApp Twitter Linkedin Email